Cargando…
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer. The gastrointestinal peptide gastrin is a trop...
Autores principales: | Burks, Julian, Nadella, Sandeep, Mahmud, Abdullah, Mankongpaisarnrung, Charoen, Wang, Juan, Hahm, Jong-In, Tucker, Robin D., Shivapurkar, Narayan, Stern, Stephan T., Smith, Jill P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008260/ https://www.ncbi.nlm.nih.gov/pubmed/29928669 http://dx.doi.org/10.1016/j.jcmgh.2018.02.013 |
Ejemplares similares
-
2297: Dietary fat stimulates growth of pancreatic cancer growth through the cholecystokinin receptor
por: Nadella, Sandeep, et al.
Publicado: (2018) -
Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression
por: Smith, Jill P., et al.
Publicado: (2023) -
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019) -
25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma
por: Gay, Martha Dee, et al.
Publicado: (2021) -
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)